Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the…
<!-- Name:DistributionId Value:8753069 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
VAX24
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of…
-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept…
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly into Infants -- -- VAX-24 is…
Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study…
-- Company Expects to Announce Topline Results from the Phase 1 and Phase 2 Portions of the Proof-of-Concept Study in October or November 2022 -- -- Vaxcyte Also Dosed First Participants in Separate VAX-24 Phase 2 Clinical Study in Adults…
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical…
-- Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned -- -- Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2…
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of…
-- Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 -- -- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 -- -- VAX-24 is a 24-Valent Pneumococcal…